Navamedic enters into Nordic distribution agreement with Biotic Pharmacon
Navamedic has entered into a distribution agreement for Woulgan® with Biotic Pharmacon. - Woulgan® will be an important and prioritised product for Navamedic, significantly strengthening our position in the advanced wound care market. We are looking forward to our partnership with Biotec and to jointly secure a solid position in this high value market, says Tom Rönnlund, CEO of Navamedic. Woulgan® is a premium priced product targeting hard to heal wounds in the professional wound care market. Clinical experience with Woulgan® demonstrate significantly improved healing, less pain and